Acquiring Company
Viyash Scientific
Acquired Company
BioForLife Italia S.r.l
Description
Viyash Scientific Limited has obtained Italian regulatory approval for its acquisition of BioForLife Italia S.r.l. The transaction involves Viyash's subsidiary, Alivira Animal Health Limited, acquiring 100% of the shares. The deal is expected to close within two months following the approval announcement. This acquisition marks a significant milestone for Viyash Scientific in the biotechnology sector.
Fundz sees it the moment Viyash Scientific makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired BioForLife Italia S.r.l?
BioForLife Italia S.r.l was acquired by Viyash Scientific, based in Hyderabad. The deal was reported on September 8, 2026. Viyash Scientific is an animal health and pharmaceutical company primarily focused on the production and distribution of formulations and active pharmaceutical ingredients (APIs). Viyash Scientific is privately held.
When did Viyash Scientific acquire BioForLife Italia S.r.l?
Viyash Scientific's acquisition of BioForLife Italia S.r.l was reported on September 8, 2026. Viyash Scientific Limited has obtained Italian regulatory approval for its acquisition of BioForLife Italia S.r.l. The transaction involves Viyash's subsidiary, Alivira Animal Health Limited, acquiring 100% of the shares. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does BioForLife Italia S.r.l do?
BioForLife Italia S.r.l. is a company engaged in the biotechnology sector. It focuses on developing life-enhancing biological products. The company aims to support health industries with innovative biotechnological solutions. It is privately held, operating in Biotechnology, and is based in Milan.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.